Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy.
Exp Hematol. 2010 Nov;38(11):1058-65. doi: 10.1016/j.exphem.2010.07.005. Epub 2010 Jul 22.
To determine if increased cell turnover in chronic myeloproliferative disorders can lead to hyperhomocysteinemia as a result of folate and/or cobalamin depletion, and contribute to oxidative stress.
The clinical role of oxidative stress was investigated by measuring reactive oxygen species (ROS), total antioxidant capacity (TAC), and total homocysteine (tHcy), folate, cobalamin, and holotranscobalamin (HoloTC) levels in 51 chronic myeloproliferative disorders patients (male-to-female ratio: 1.1; median age: 64 years; range, 40-84 years), including 42 with primary myelofibrosis and 9 with post-polycythemia vera myelofibrosis.
Myelofibrotic patients had higher tHcy (p = 0.0201) and an unbalanced oxidative status (higher ROS and lower TAC levels; p < 0.0001) than controls. Presence of diabetes or another neoplasia was associated with higher ROS levels (p < 0.05), splenomegaly, hepatomegaly, and peripheral blasts with lower HoloTC levels (p < 0.005). The most severe forms of myelofibrosis (2-3) were associated with lower TAC (p = 0.045) and HoloTC levels (p = 0.017). Patients with Janus kinase-2 mutations had lower HoloTC levels (p = 0.0059). HoloTC deficiency was more frequently associated with Janus kinase-2 homozygosity (p < 0.0003).
Our findings suggest that the determination of HoloTC, tHcy, ROS concentrations, and TAC, can identify latent cobalamin deficiency and provide a rational basis for correcting the increased oxidation associated with disease progression.
确定慢性骨髓增生性疾病中细胞更新增加是否会导致叶酸和/或钴胺素耗竭引起的高同型半胱氨酸血症,并导致氧化应激。
通过测量活性氧(ROS)、总抗氧化能力(TAC)和总同型半胱氨酸(tHcy)、叶酸、钴胺素和全钴胺素(HoloTC)水平,研究氧化应激的临床作用,在 51 例慢性骨髓增生性疾病患者(男/女比例:1.1;中位年龄:64 岁;范围,40-84 岁)中,包括 42 例原发性骨髓纤维化和 9 例真性红细胞增多症后骨髓纤维化。
与对照组相比,骨髓纤维化患者的 tHcy 水平更高(p=0.0201),氧化状态失衡(ROS 水平升高,TAC 水平降低;p<0.0001)。患有糖尿病或其他肿瘤的患者 ROS 水平较高(p<0.05),存在脾肿大、肝肿大和外周原始细胞的患者 HoloTC 水平较低(p<0.005)。骨髓纤维化最严重的形式(2-3 级)与 TAC(p=0.045)和 HoloTC 水平(p=0.017)降低有关。Janus 激酶-2 突变患者的 HoloTC 水平较低(p=0.0059)。HoloTC 缺乏更常与 Janus 激酶-2 纯合子有关(p<0.0003)。
我们的发现表明,测定 HoloTC、tHcy、ROS 浓度和 TAC 可以确定潜在的钴胺素缺乏,并为纠正与疾病进展相关的氧化增加提供合理的依据。